Inovio Pharmaceuticals Inc (INO)
4.265
-0.50
(-10.59%)
USD |
NASDAQ |
Nov 15, 16:00
4.28
+0.02
(+0.35%)
Pre-Market: 20:00
Inovio Pharmaceuticals Research and Development Expense (TTM): 76.76M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 76.76M |
| March 31, 2024 | 77.41M |
| December 31, 2023 | 86.68M |
| September 30, 2023 | 111.54M |
| June 30, 2023 | 129.13M |
| March 31, 2023 | 161.85M |
| December 31, 2022 | 187.65M |
| September 30, 2022 | 237.83M |
| June 30, 2022 | 251.83M |
| March 31, 2022 | 266.17M |
| December 31, 2021 | 249.24M |
| September 30, 2021 | 183.24M |
| June 30, 2021 | 162.61M |
| March 31, 2021 | 114.18M |
| December 31, 2020 | 94.25M |
| September 30, 2020 | 89.95M |
| June 30, 2020 | 82.63M |
| March 31, 2020 | 82.74M |
| December 31, 2019 | 88.02M |
| September 30, 2019 | 92.38M |
| June 30, 2019 | 95.09M |
| March 31, 2019 | 95.07M |
| December 31, 2018 | 95.26M |
| September 30, 2018 | 93.53M |
| June 30, 2018 | 97.19M |
| Date | Value |
|---|---|
| March 31, 2018 | 98.61M |
| December 31, 2017 | 98.57M |
| September 30, 2017 | 97.84M |
| June 30, 2017 | 99.31M |
| March 31, 2017 | 95.07M |
| December 31, 2016 | 88.71M |
| September 30, 2016 | 80.40M |
| June 30, 2016 | 69.50M |
| March 31, 2016 | 66.55M |
| December 31, 2015 | 57.79M |
| September 30, 2015 | 51.43M |
| June 30, 2015 | 42.38M |
| March 31, 2015 | 35.30M |
| December 31, 2014 | 34.10M |
| September 30, 2014 | 31.25M |
| June 30, 2014 | 29.68M |
| March 31, 2014 | 24.48M |
| December 31, 2013 | 21.37M |
| September 30, 2013 | 19.41M |
| June 30, 2013 | 18.94M |
| March 31, 2013 | 19.06M |
| December 31, 2012 | 17.98M |
| September 30, 2012 | 17.70M |
| June 30, 2012 | 19.72M |
| March 31, 2012 | 19.65M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
76.76M
Minimum
Jun 2024
266.17M
Maximum
Mar 2022
143.88M
Average
114.18M
Median
Mar 2021
Research and Development Expense (TTM) Benchmarks
| Novavax Inc | 451.49M |
| Baxter International Inc | 754.00M |
| AIM ImmunoTech Inc | 9.03M |
| Protalix BioTherapeutics Inc | 12.62M |
| Armata Pharmaceuticals Inc | 32.40M |